Studying New Ways to Target Adult T-Cell Leukemia and Lymphoma Cells
Studies cell samples from adults with resistant T-cell leukemia or lymphoma, testing drug combinations.
Key facts
- Who runs it
- Istituto Oncologico Veneto IRCCS
- Where
- Naples and Padova, ItalySee the 2 sites
- Trial code
- Registry title
- Novel Therapeutic Approach for Human T-cell Malignancies
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 18 Mar 2025
- Expected to end
- 1 Mar 2027
- Type of study
- Observational
- Treatments tested
- Translation analysis
- Record updated
- 6 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with T-cell leukemia or lymphoma. Their cells are tested in the laboratory with drug combinations.
- Age
- Older than 18 years (minimum age 18 years)
- Sex
- Both sexes can join
- Disease stage
- Pre- and post-thymic T-cell leukemia/lymphoma
Main reasons for not taking part
- A serious illness or medical condition that does not allow management with standard treatment protocols
- Uncontrolled active infection
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with pre- and post-thymic T-cell leukemia/lymphoma
- Patients of both sexes
- Age of patients older than 18 years
- Patient is willing to provide written and signed informed consent for participation in the study
Who cannot take part
- -Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection
Where in Italy
- Istituto Nazionale Tumori Fondazione G. PascaleNaples, ItalyContact: Antonio Pinto, MDTaking people
- Istituto Oncologico VenetoPadova, ItalyContact: Michele Gottardi, MDTaking people
About the trial
What the trial wants to find out
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
Read full original descriptionShow less
Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined.
The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
Treatments tested
- Translation analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Identification of Targetable Vulnerabilities in Redox Homeostasis Pathways as a Novel Therapeutic Approach for Human T-cell Malignancies
- Plain-language title
- Studying New Ways to Target Adult T-Cell Leukemia and Lymphoma CellsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 August 2026